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I t is well established that cannabis use causes acute impair-ment in the ability of the brain to hold information (ie, cogni-tive capacity).Hence, temporarydeficits occur in learning and
memory, attention, and workingmemory.
Does Cannabis Use Affect Cognitive Capacity?
Cannabis use causes acute impairment of learning and memory, at-
tention, and working memory,1-3 but it is less clear if cannabis use is
associated with enduring neuropsychological impairment. Case-
control studiescomparingnonintoxicatedheavycannabisuserswith
nonusershavefairlyconsistentlyshownthatheavycannabisusersper-
formworseonneuropsychological tests.Forexample,theresults from
2 separate meta-analyses4,5 showed that compared with nonusers,
nonintoxicatedcannabisusersperformworseonmeasuresofglobal
neuropsychological function,with effect sizes for specific neuropsy-
chological domains (executive functions, attention, learning and
memory, motor skills, and verbal abilities) of approximately one-
third of a standard deviation or less. When analyses in the second
meta-analysis5werelimitedto13studiesofcannabisuserswithat least
1month of abstinence, therewas no discernible difference between
cannabis users and nonusers on neuropsychological test perfor-
mance, suggesting that neuropsychological functionsmight recover
withprolongedabstinence.Evidencesuggests that themagnitudeof
neuropsychological impairmentandtheextent towhich itpersistsaf-
ter abstinencemaydependon the frequency anddurationof canna-
bis use, length of abstinence, and age at onset of use.6
Emerging evidence suggests that adolescentsmay be particu-
larly vulnerable to the adverse effects of cannabis use. Adoles-
cence represents a critical neurodevelopmental period character-
ized by marked synaptic pruning and increased myelination.7
Moreover, the endocannabinoid system appears to be involved in
the regulation of key neurodevelopmental processes,7 suggesting
that the introduction of exogenous cannabinoids during adoles-
cencecoulddisruptnormalbraindevelopment.Animal researchsup-
ports thepossibility that adolescence represents aperiodofheight-
enedvulnerability tocannabisexposure.7Forexample,pubertal rats
treatedwithacannabinoidagonist showedpersistentdeficitsonob-
ject recognition tasks, whereas adult rats did not.8,9 Accumulating
evidence inhumansparallels theanimal findings.6Forexample, sev-
eral studies have shown that earlier age at onset of cannabis use is
associated with greater neuropsychological impairment,10,11 and a
2012 population-representative longitudinal study12 documented
that adolescent-onset (butnot adult-onset) persistent cannabis us-
ers showed neuropsychological decline from ages 13 to 38 years.
Neuroimaging investigations of adolescent and adult cannabis
users have yielded somewhat inconsistent findings. Recent re-
viewshavedemonstrated that there is fairly clear evidenceof struc-
tural alterations in medial temporal (amygdala and hippocampus),
frontal,andcerebellar regionsassociatedwithcannabisexposure.13,14
However, another recent study15 that carefully matched partici-
pantsonalcohol intake reportednoevidenceofmorphologicalbrain
alteration among adolescent or adult cannabis abusers, suggesting
the possibility that comorbid alcohol use could explain someof the
morphological alterations observed in prior research. There is also
some evidence that cannabis users have impaired neural connec-
tivity. For example, a study16 of adults with long histories of heavy
cannabisuseshowedevidenceofdecreasedconnectivity in the right
fimbria of the hippocampus (fornix) and the splenium of the cor-
pus callosum and the commissural fibers. Finally, functional mag-
netic resonance imaging investigationshave suggested that canna-
bis users show altered neural activity both in the resting state and
during cognitive testing.14 For example, male adolescent cannabis
With a political debate about the potential risks and benefits of cannabis use as a backdrop,
the wave of legalization and liberalization initiatives continues to spread. Four states
(Colorado, Washington, Oregon, and Alaska) and the District of Columbia have passed laws
that legalized cannabis for recreational use by adults, and 23 others plus the District of
Columbia now regulate cannabis use for medical purposes. These policy changes could
trigger a broad range of unintended consequences, with profound and lasting implications for
the health and social systems in our country. Cannabis use is emerging as one amongmany
interacting factors that can affect brain development andmental function. To inform the
political discourse with scientific evidence, the literature was reviewed to identify what is
known and not known about the effects of cannabis use on human behavior, including
cognition, motivation, and psychosis.
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users showed increased blood oxygen level–dependent functional
magnetic resonance imaging activity in the prefrontal cortex dur-
ing a novel workingmemory task, whichwas interpreted to reflect
inefficient processing.17 This observation is consistentwith studies
measuring resting functional connectivity inadolescentcannabisus-
ers that have documented altered patterns of connectivity affect-
ing interhemispheric traffic18 and the frontotemporal network.19,20
Some evidence suggests that cannabidiol, another cannabinoid
found in the cannabis plant (although usually at very low concen-
trations), may protect against some of the harmful effects of tetra-
hydrocannabinol (THC) on cognition.21,22
Thereareareas that require further research.First,observeddif-
ferences in neuropsychological test performance, as well as in brain
structure and function,might reflect individual differences that pre-
cede cannabis use. Progress has been limited by reliance on cross-
sectional investigationscomparingcannabisusersandnonusers.Two
longitudinalstudies12,23withbefore-and-afterneuropsychologicaltest-
inghaveshownevidenceofwithin-individualdecline inneuropsycho-
logical functionassociatedwith cannabis use. The findings couldnot
beexplainedbyalcoholandotherdruguse,psychiatricdisorders, low
socioeconomicstatus,orahostofotherpotentialconfounds.However,
the number of cannabis users in these cohorts was small, and brain
imagingwasnotperformed.Yet,neuroimagingfindingsraisethepos-
sibilitythatsmallerregionalbrainvolumesamongcannabisuserscould
bepartiallyaccountedforbypreexistingdifferences.Forexample,one
prospectivelongitudinalstudy24showedthatsmallerorbitofrontalcor-
texvolumesincreasedriskforadolescentcannabisuse initiation,while
astudy25of twinsandsiblings foundthat reducedamygdalavolumes
amongcannabisuserscouldbeexplainedbyfamilial factors.Takento-
gether, these findingshighlight theneed for longitudinal studies that
follow up adolescents frombefore to after initiation of cannabis use
andcombineneuropsychological testingwithneuroimaging.TheAdo-
lescentBrainCognitiveDevelopmentStudy,26a largeprospectiveNa-
tional Institutes ofHealth–funded investigation of children ages9 to
10yearswhowillbefollowedupforat least 10years, isbeing launched
to in partmeet this need.
A second area that is ripe for further research pertains to the
need to reconcile neuroimaging findings with neuropsychological
test performance. Current neuroimaging evidence is inconsistent,
andalterations inbrain structure and function tendnot to correlate
withdecrements inneuropsychological test performance.27 Larger
samples areneeded for imaging alongwith careful considerationof
participant characteristics, including comorbid use of alcohol and
other drugs and length of abstinence from cannabis.
Third,morework is needed toanswer thequestion “Howmuch
cannabis use is toomuch?” Becausemany study samples include a
large portion of individuals with cannabis dependence (as defined
by the DSM-IV), it is unclear if the effects generalize to individuals
with less severe cannabis use disorders and to more casual recre-
ational users.
Fourth, because of the potential effect of exogenous cannabi-
noids on brain development, more work is needed to answer the
question “Atwhat age is cannabis usemost harmful?” In addition to
studying theeffectsof cannabisuseonadolescents, research is also
needed to understand older adults’ susceptibility to cannabis-
related neuropsychological impairment. This population experi-
ences changes in brain plasticity and age-related cognitive decline
thatmaymake themmorevulnerable to theeffectsof cannabisuse.
Fifth, recent evidence suggests sex differences in neuropsy-
chological deficits associated with cannabis use.1,28 Hence, future
work shouldhelp clarifymechanismsunderlying thesepotential sex
differences.
Sixth, genetic factors such as polymorphisms in the COMT
(OMIM 116790) andAKT1 (OMIM 164730) genesmay also increase
susceptibility tocannabis-relatedneuropsychological impairment.29
Other examples include a recent study30 that showed that THC
causedacute impairmentofworkingmemory forCOMTVal/Val car-
riers (butnotMetcarriers), aswell asanotherstudy31of3population-
based cohorts that showed that cannabis use was associated with
decreasedcortical thicknessamongmale individualsathigh (butnot
low) genetic risk for schizophrenia as indexed by a polygenic risk
score.Thepossibility that individualdifferencesamongcannabisus-
ers may have significant effects and be predictive of the extent of
adverse consequences suggests that recent approaches to lever-
aging genetic information to create polygenic risk scores might be
useful toward advancing the study of cannabis use and neuropsy-
chological function.
Does Cannabis Use Decrease Motivation?
As early as the late 19th century, the Indian Hemp Drugs
Commission32 reportedthatheavycannabisusewasassociatedwith
apathy,definedas reducedmotivation forgoal-directedbehavior.33
However, it was only after the marked increase in cannabis use of
the1960sthat theamotivationaleffectsofchroniccannabisusewere
linked to impairments in learningandsustainedattention. The term
cannabis amotivational syndromewasproposedbyMcGlothlin and
West,34whocharacterized it asapathyanddiminishedability tocon-
centrate, followroutines,or successfullymasternewmaterial.While
there has always been some controversy around the need for de-
fining such a distinct phenotype, there is evidence that long-term
heavy cannabis use is associated with educational underachieve-
mentand impairedmotivation,whichhavebeenproposed tobepo-
tential mediators of poorer functional outcomes.35
There is both preclinical and clinical evidence supporting the
view that cannabis use is associatedwith an amotivational state. In
rhesusmonkeys, heavy chronic cannabis use or administration has
been found to dampenmotivation, asmeasured onprogressive ra-
tioandconditionedpositionrespondingoperanttests.36There ispre-
liminary laboratoryevidence supportinganassociationbetween re-
duced motivation for reward-related behavior in cannabis users
compared with control individuals.37 Because these findings ap-
pear tobe related to repeateddoses of THC, it is likely that reduced
motivation is onepathway to impaired learning, as THC candisrupt
reward-based learning.38 In support of this theory, cannabis users
exhibit reduced striatal dopamine synthesis capacity,39 with an in-
verse relationship to amotivation. Inasmuch as dopamine signaling
sustains motivation,40 impaired dopamine synthesis could under-
lie the amotivational state in cannabis users. Similarly, imaging in-
vestigations documenteddecreased reactivity to dopamine stimu-
lation in cannabis users that was associated with negative
emotionality and that would also contribute to reduce engage-
ment in non–drug-related activities.41
Amotivation inchronicheavyusersmayalso reflect the fact that
cannabis itself hasbecomeamajormotivator, sootheractivities (eg,
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schoolwork) becomedemoted in the individual’s rewardhierarchy.
Indeed, addiction to thedrugoccurs in about9%ofusers42whoap-
pear more vulnerable than other users because of a multiplicity of
variables, includingageatonset, levelofuse, andenvironmental and
genetic factors.
What remains to be seen iswhether changes in the concentra-
tionof theactive ingredientsofcannabiscouldaffect the riskofamo-
tivationoraddiction.Thecannabisplantcontainsapproximately 100
uniquecannabinoid ingredients,withthemostresearchedbeingTHC
and cannabidiol. Over the last 30 years, levels of THC in street can-
nabis have increased.43 Of these 2 compounds, only THC deter-
mines the level of the subjective high. Alongside a blunted dopa-
mine system,41 chronic heavy use of cannabis is associated with
changes in the endocannabinoid system, including reduced levels
of anandamide (an endogenous ligand for the cannabinoid recep-
tors) in human cerebrospinal fluid44 and reduced levels of canna-
binoid 1 receptors.45 Indeed, a growing preclinical literature impli-
cates cannabinoid 1 receptors and their endogenous ligands in the
motivational effects of cannabis use.46 Similar to the association of
cannabis use with cognitive impairment, it is impossible to unam-
biguously establishwhether cannabis use is a cause, consequence,
or correlate of alteredmotivation. Furtherwork is needed todistin-
guishwhether thepotential amotivational effectsare related tocan-
nabis use disorders rather than cannabis use per se.
Does Cannabis Use Increase the Risk for Psychosis?
Oneof themostpersistent controversies vis-à-vis cannabis useper-
tains to itseffecton the riskofpsychiatricdisorders,particularlypsy-
chotic disorders and full-blown schizophrenia. Longitudinal inves-
tigationsshowaconsistentassociationbetweenadolescentcannabis
useandpsychosis.Cannabisuse is consideredapreventable risk fac-
tor for psychosis.47 The link between cannabis use and schizophre-
nia could stem from direct causality, gene-environment interac-
tions, sharedetiology, or self-medication forpremorbid symptoms,
although some researchers have suggested that only the first 3 hy-
potheses remain open questions.48-50 The sporadic emergence of
conflictingdata shouldnotbesurprisinggiven thenatureof thispar-
ticular biological problem. For example, the effects of cannabis ex-
posuremaybemodest in the totalpopulationandcontingenton the
presence of multiple genetic and environmental variables. On the
otherhand, thereremainsa lingeringand legitimatecontroversyover
what proportionof psychosis risk canbe attributed to cannabis use
and the extent towhich individuals without genetic predisposition
can be precipitated into the illness.
Despite this ambiguity, there is strongphysiological andepide-
miological evidence supporting amechanistic link between canna-
bisuseandschizophrenia.Tetrahydrocannabinol (particularlyathigh
doses) can cause acute, transient, dose-dependent psychosis
(schizophrenia-like positive and negative symptoms).51 In addi-
tion, prospective, longitudinal, epidemiological studies consis-
tently report an associationbetween cannabis use and schizophre-
nia in which cannabis use precedes psychosis52 independent of
alcohol consumption53 and even after removing52,54 or controlling
for55,56 those individuals who had used other drugs. Although the
prodromal period before full-blown illness complicates determin-
ingwhether or not cannabis use precedes symptoms or reflects an
attempt to treat them, cannabis use preceded psychosis in these
studies.52,54,57 Moreover, persistent cannabis use after a first epi-
sode is associatedwithpoorerprognosis58evenafter controlling for
other substance use.59
Although cannabis use may have long been discontinued be-
fore the onset of psychosis, the age at which cannabis use begins
appears to correlatewith the age at onset of psychosis, suggesting
a causal relationship to initiating psychosis that is independent of
actualuse.49,60,61Theassociationbetweencannabisuseandchronic
psychosis (including a schizophrenia diagnosis) is stronger in those
individuals who have had heavy or frequent cannabis use during
adolescence,53,54,60,62,63 earlier use,52 or use of cannabiswith high
THC potency.60,62 From these studies, ever use of cannabis is esti-
mated to increase the riskof schizophreniabyapproximately2-fold,
accounting for8%to14%ofcases,55with frequentuseoruseofcan-
nabis with high THC potency increasing the risk of schizophrenia
6-fold.53 Consistent with this notion, the greater cannabinoid re-
ceptor type1availability thathasbeenreported insomepatientswith
schizophrenia,64,65andwhichcorrelateswithnegativesymptoms,66
may also contribute to an enhanced sensitivity to the psychoto-
genic effects of cannabis use. It is important tohighlight in this con-
text thatmost individualswhouse cannabis donot develop schizo-
phrenia. Therefore, while cannabis use is neither necessary nor
sufficient for the development of schizophrenia, available evi-
dence suggests that cannabis use may initiate the emergence of a
lastingpsychotic illness in somepersons (most likely those individu-
alswith a genetic vulnerability),67 and this findingwarrants serious
consideration from the point of view of public health policy.
It is becoming increasingly clear that acute psychosis, schizo-
phreniform disorder, and schizophrenia are the result of interac-
tions amongmany different factors operating at various levels. For
example, having a close family member with schizophrenia is the
strongest known risk factor for schizophrenia, yet few investiga-
tions linking cannabis use and schizophrenia have controlled spe-
cifically for familial schizophrenia risk.Theresultsofonestudy68sug-
gested that cannabis use may lead to schizophrenia in individuals
with a family history of the disease compared with those individu-
als without a family history. However, controlling for familial risk in
one large epidemiological study69 considerably attenuated but did
notcompletelyeliminate theassociationofcannabisusewithschizo-
phrenia, with odds ratios of 3.3 and 1.6with 3-year and 7-year tem-
poral delays, respectively.
Possible3-way interactionsamonggenotype, cannabisuse, and
psychosis have also been explored. The DRD2 genotype (OMIM
126450) influenced the likelihood of a psychotic disorder in indi-
vidualswhousedcannabis.70Amongoccasional cannabisusers and
daily cannabis users, carriers of the DRD2, rs1076560, T allele had
3-fold and 5-fold higher likelihoods of a psychotic disorder,
respectively.70The functionalCOMTVal-158polymorphismhasalso
been reported to moderate the effect of adolescent cannabis use
on adult psychosis, such that carriers of this allele weremore likely
todevelopschizophreniformdisorder if theyusedcannabis thannon-
carriersof theallele.67 InanexperimentalTHCstudy,71COMTVal car-
riershadgreatercognitive impairmentafterTHCexposureandmore
psychotic symptoms than COMTMet/Met carriers. An AKT1 geno-
typebycannabis use interactionhas alsobeen reported,with those
individuals having C/C rs2494732 genotypes and also using canna-
bis having a 2-fold higher chance of experiencing a psychotic
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disorder.72 In another study,73 those participants who were carri-
ersof theAKT1C/Cgenotypewitheveruseof cannabis anddailyuse
showed2-fold and7-fold increased likelihoodsof a psychotic disor-
der, respectively, compared with users and daily users who were
T/T carriers.
The results supporting thehypothesis that somegenevariants
influence the likelihoodof developing schizophrenia contingent on
certain environmental exposure (eg, cannabis use) reflect tenta-
tive findings among small numbers of individuals that require
replication.74 An alternative explanation is that individuals at ge-
netic high risk for schizophreniamaybemore likely to use cannabis
throughasharedgenetic risk for schizophreniaandcannabisusedis-
order. Indeed, the recent report froma largegenome-wideassocia-
tionstudy75of anassociationbetweenschizophrenia riskalleles and
cannabis use suggests that part of the association between schizo-
phrenia and cannabis use may be because of a shared genetic eti-
ology. However, the use of cannabis with high THC potency was
strongly associatedwith later developmentof schizophrenia inone
study,63 while the recently reported polygenic risk score for
schizophrenia76 was unrelated to cannabis use or the potency of
cannabis used.77
Finally, as in chronic or heavy cannabis users,78 patients with
schizophrenia also show reduced volumes in the amygdala and
hippocampus.79Thisobservationcouldhelpexplain theworseclini-
caloutcomes in individualswithschizophreniawhousecannabisbe-
cause thosemorphological changesare likely tounderlie or contrib-
ute to the cannabis-associated exacerbation of symptoms seen in
schizophrenia.80
Conclusions
Decades of ill-informed and porous legal and illegal drug regula-
tions have exacted a devastating public health toll from our soci-
ety. It is clear that the cumulative effect of nicotine exposure and
alcohol use onmorbidity andmortality has been staggering, as has
thedisproportionate criminal justice influenceof the “warondrugs”
onminority anddisadvantagedpopulations. Current efforts tonor-
malize cannabis use are being driven largely by a combination of
grassroots activism, pharmacological ingenuity, and private profi-
teering, with a worrisome disregard for scientific evidence, gaps in
ourknowledge,or thepossibilityofunintendedconsequences.Given
the critical andwide-ranging roleof theendocannabinoid system in
thebrain,81-83 the increasingprevalenceof cannabisuseandusedis-
orders over the last decadeand the increasedTHCconcentration in
cannabis plants, there is a need to clarifywhich aspects of cannabis
exposure (eg, age at initiation, quantity used, frequency of use, du-
rationofuse, andpotencyof cannabisused) confer thegreatest risk
for the development of cannabis use disorder or for other adverse
consequences (ie, cognitive deficits, lack ofmotivation, or psycho-
sis). In addition, there are many unanswered questions more di-
rectly linked to the soundness of hastily implemented policies. For
example, will advertising be permitted? What patterns of use and
associated toxic effects will emerge if and when “e-joints” become
widespreadoreventhenormamongadolescents?Howwill expand-
ing the pool of pregnant cannabis users affect the developmental
trajectories of exposed fetuses? Finally, what are the conse-
quences of secondhand cannabis smoke?
If we stay the current course, we are likely to uncover effects
that were rare in the past only because the use was not as wide-
spread as that of legal drugs. Vulnerable populations such as chil-
dren,adolescents, theelderly,or individualswithotherdisordersmay
experiencenovel toxiceffects (aswell as thepotential benefits). The
changing landscapeof cannabisuse (eg, strainswithhigherTHCpo-
tency,newroutesofadministration[“vaping”andedibles], andnovel
drugcombinations)andacultureof rapidlychangingnormsandper-
ceptions raise thepossibility thatourcurrent, limitedknowledgemay
only apply to the ways in which the drug was used in the past.
The areas explored in this article, which reflect only a subset of
themultiple effects of cannabis use on the brain and body, belie the
ubiquity of the cannabinoid signaling system. Therefore, in addition
toexpandingourbasicresearchefforts,weshouldtryto learnasmuch
andas rapidly aswecan fromtheongoingchanges in local policies to
minimize the harms andmaximize the potential benefits.
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